KaloBios Buys Chagas Drug With Eye On Priority Review Voucher
This article was originally published in Scrip
Executive Summary
No one else in the biopharmaceutical industry is viewed more negatively right now than Martin Shkreli, but the former hedge fund investor and current Turing Pharmaceuticals CEO is having a positive effect on KaloBios Pharmaceuticals Inc., whose stock surged when Shkreli took over the company and rose again after the once-troubled biotech firm bought a drug for Chagas disease.